Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma

Figure 2

(p)FAK, (p)Src expression, and DNA damage (γH2AX) following defactinib and dasatinib combination treatment in DSRCT, ES, ARMS, and ERMS cell lines. FAK, pFAK (Tyr397), Src, pSrc (Tyr416), γH2AX (Ser139), and GAPDH expressions at baseline, post-24-h single-agent defactinib or dasatinib treatment, and post-24-h combination treatment with defactinib and dasatinib in the JN-DSRCT-1, TC32, Rh30, and RD cell lines assessed by Western blot analysis.